AMHR2

Broad coverage extended to Japan and related regions SAN JOSE, Calif., Jan. 23, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that its collaborator, Cleveland Clinic, has received a "Decision to Grant" notice from the Japan Patent Office (JPO) for the patent application titled "Ovarian Cancer Vaccines." Anixa Chairman and CEO Dr. Amit Kumar commented, "This new Japanese patent extends the expanded claims for this novel ovarian cancer vaccine technology to another geographic region, joining the European and U.S. patents awarded last year. As the exclusive worldwide licensee of the technology, we highly value the broad protection this patent provides as our research and development continues. If our vaccine is approved, one of the most aggressive gynecological cancers could be prevented from ever developing in women globally." The Ovarian Cancer Vaccines patent was invented by the late Dr. Vincent Tuohy, Dr. Suparna Mazumder, and Dr. Justin Johnson of Cleveland Clinic. The researchers demonstrated in pre-clinical studies that vaccination against the extracellular domain of anti-Müllerian hormone receptor II (AMHR2-ED) significantly inhibits tumor growth and enhances overall survival. The results indicate that vaccinating women against AMHR2-ED could provide safe and effective preemptive immunity against epithelial ovarian carcinoma, the most common form of ovarian cancer. Anixa is the exclusive worldwide licensee for the vaccine technology from Cleveland Clinic, a nonprofit, multispecialty academic medical center. Preclinical work on the vaccine is supported by the National Cancer Institute's PREVENT Program, a peer-reviewed program designed to support development of the best ideas in cancer prevention. About Anixa Bioscience's Ovarian Cancer Vaccine Anixa's ovarian cancer vaccine takes advantage of endogenously produced proteins that have a function at certain times in life, but then become "retired" and disappear from the body. One such protein is the extracellular domain of anti-Müllerian hormone receptor II (AMHR2-ED) which regulates growth and development of egg-containing follicles in the ovaries and is expressed throughout much of a woman's life, with expression naturally and markedly declining during menopause, but which is present in the majority of endothelian ovarian carcinomas. Activating the immune system against this "retired" protein provides preemptive immune protection against emerging ovarian tumors that express AMHR2-ED. The vaccine also contains an adjuvant that activates an innate immune response, which allows the immune system to mount a response against emerging tumors to prevent them from growing. This vaccine technology was invented by the late Dr. Vincent Tuohy, who was the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research in the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. Dr. Tuohy was inventor of the technology, which Cleveland Clinic exclusively licensed to Anixa Biosciences. He was entitled to a portion of the commercialization revenues received by Cleveland Clinic and also held equity in Anixa. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T cell (CER-T) technology. The Company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit or follow Anixa on Twitter, LinkedIn, Facebook and YouTube. Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Contact: Mike Catelani President, COO & CFO [email protected] 408-708-9808 SOURCE Anixa Biosciences, Inc.

Collaboration to study a novel mechanism of melatonin receptor action outside of the CNS for treating PCOS NEW YORK--(BUSINESS WIRE)-- Celmatix Inc., a leading women’s health biotech focused on ovarian biology, and Aché Laboratórios, a leading Brazilian pharmaceutical company, today announced a collaboration and license option agreement to jointly investigate a novel peripherally preferred melatonin receptor agonist, discovered by Aché, for Women's Health indications. Today’s news follows Celmatix’s April announcement of the second of its three internal drug programs, targeting melatonin receptors outside of the central nervous system (CNS) to address a critical gap in the market for effective first-line treatments for a range of women’s health indications, starting with polycystic ovary syndrome (PCOS). Under the terms of the agreement Aché and Celmatix will collaborate to assess the potential of the drug candidate in well established in vivo models of PCOS. Following successful completion of these studies, the companies intend to enter into a separate license and development agreement. “We are excited to join efforts with Celmatix to explore the role of melatonin receptors in the context of PCOS, as well as to investigate the potential of a novel peripherally preferred melatonin receptor agonist discovered at Aché in restoring ovary function in these patients,” said José Vicente Marino, CEO of Aché. “Aché’s expertise in the research, development, and commercialization of medicines, in conjunction with Celmatix’s cutting edge know-how in the identification and validation of drug targets in the Woman’s Health field, will synergize for advancing the knowledge about PCOS and developing new medicines for treating the disease.” PCOS is known primarily for being one of the most common causes of female infertility, affecting around 15% of women of reproductive age. However, disrupted ovarian physiology in women experiencing PCOS has also been shown to impact endocrine, immune, metabolic, cardiovascular, and mental health functions. Despite the prevalence of PCOS, no drug has ever been developed specifically to treat it. The existing standard of care for PCOS focuses on symptom management, including birth control pills to regularize periods, metformin to address insulin resistance, statins to control high cholesterol, ovarian stimulation for ovulatory dysfunction, and cosmetic procedures to remove unwanted hair. The Celmatix program is aimed at restoring ovarian function in a way that addresses the root cause of all these symptoms. Celmatix Founder and CEO, Dr. Piraye Yurttas Beim explained, “We are thrilled to be able to advance our PCOS Melatonin Program through our collaboration with Aché. We know there is a compelling link between melatonin signaling outside of the CNS and endocrine, metabolic, and reproductive traits in women with PCOS. However, melatonin and existing selective melatonin receptor agonists are not viable therapeutics for ovarian health conditions because they have potent CNS-activity that creates significant side effects, including nausea and drowsiness. By focusing on melatonin receptor action outside of the CNS, through this joint development and licensing option agreement with Aché, we are one important step closer to being able to offer relief to the millions of women with a range of ovarian health conditions, including PCOS.” About Aché Laboratórios Farmaceuticos S.A. Aché is a 56-year-old Brazilian pharma company with a leading reputation in the prescription and specialty fields. The company is one of the largest pharmaceutical corporations in Brazil, with five industrial plants that manufacture solids, liquid, semi-solids, parenteral drugs, antibiotics, and contraceptives. Aché has approximately 5,000 employees and more than 300 branded products in its portfolio, distributed across several therapeutic areas, including Woman’s Health. Aché has been considered the most innovative pharmaceutical company in Brazil in the past years, with nearly 350 employees dedicated to drug discovery, pharmaceutical sciences, preclinical and clinical development activities, as well as a business development team focused on partnering activities. The company has launched several innovative products and formed global partnerships in the last years with leading biotech and pharma companies to discover and develop new molecules for diseases with significant unmet needs. About Celmatix Celmatix Inc. is a preclinical-stage women’s health biotech focused uniquely on ovarian biology. With its growing pipeline of innovative drug programs including an AMHR2 agonist program focused on ovarian aging, novel melatonin agonist program for PCOS, oral FSH for infertility, and collaborations with industry leaders, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health. Celmatix’s proprietary multi-omic ovarian health platform, the world’s largest of its kind, is the foundation of the company’s novel pipeline of first-in-class therapies. For more information, visit the company’s website at View source version on businesswire.com: Contacts Ariel Kramer ariel@klovercommunications.com Source: Celmatix Inc. View this news release online at:

SAN JOSE, Calif., July 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa's novel ovarian cancer vaccine technology, which has been exclusively licensed from, and is being developed in partnership with, Cleveland Clinic. The patent is titled "Ovarian Cancer Vaccines," and covers nucleic acid-based delivery of the vaccine. The lead inventor is the late Dr. Vincent Tuohy of Cleveland Clinic. This ovarian cancer vaccine targets the extracellular domain of anti-Müllerian hormone receptor 2 (AMHR2-ED), which is expressed in the ovaries but disappears as a woman reaches and advances through menopause. However, AMHR2-ED is expressed again in the majority of ovarian cancers. Dr. Amit Kumar, Chairman and CEO of Anixa, stated, "We are pleased to receive this notice of allowance from the USPTO, providing additional protection for our ovarian cancer vaccine technology, including a possible mRNA vaccine." Dr. Kumar added, "Preclinical work to advance the vaccine is ongoing with support from the PREVENT Program at the National Cancer Institute (NCI), which supports preclinical innovative interventions and biomarkers for cancer prevention and interception." About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program that uses a novel type of CAR-T known as chimeric endocrine receptor T-cell (CER-T) technology, and is being developed in collaboration with Moffitt Cancer Center. The Company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit or follow Anixa on Twitter, LinkedIn, Facebook and YouTube. Forward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Contacts: Stephen Kilmer Investor Relations [email protected] 646-274-3580 Mike Catelani President, COO & CFO [email protected] 408-708-9808 SOURCE Anixa Biosciences, Inc.